Printed From BioPortfolio.com

AbbVie and Amgen Resolve Humira Patent Disputes

18:54 EDT 28 Sep 2017 | PharmPro

News

AbbVie announces global resolution of Humira (adalimumab) patent disputes with Amgen. Agreements provide non-exclusive license to Amgen for Humira-related intellectual property in the U.S. effective Jan. 31, 2023, other nations on different dates.

Contributed Author:

AbbVie

Original Article: AbbVie and Amgen Resolve Humira Patent Disputes

Give dad the gift of knowledge. Order his DNA Ancestry kit this Father's Day for $99 at 23andMe! Ord

Quick Links
Advanced Search | Login | Subscribe | RSS

Quick Search

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Antibodies
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...

News Quicklinks

Search Biotech, Medical and Healthcare News

Biotech News by Article Type

Biotech News by Location

BioPortfolio Bloggers

Publishing Your News on BioPortfolio

Recent Visitor News Searches

Topics

AbbVie and Amgen Resolve Humira Patent Disputes

More From BioPortfolio on "AbbVie and Amgen Resolve Humira Patent Disputes"

Relevant Topics

News Quicklinks